Basilea Receives $5 Million Milestone Payment
Pharmaceutical company Basilea has received a $5 million milestone payment following strong sales performance of its antifungal drug, Cresemba® (isavuconazole), in the Asia Pacific region and China. The payment triggers a key agreement with a partner, according to company filings.
The financial boost comes as Cresemba continues to gain traction in key Asian markets. The drug is used to treat invasive aspergillosis and mucormycosis, serious fungal infections. This milestone payment underscores the growing demand for effective antifungal treatments in the region.
Basilea did not disclose specific sales figures that triggered the payment, but indicated the results exceeded expectations. The company is focused on expanding Cresemba’s global reach and maximizing its commercial potential. The decision highlights the increasing importance of the Asia Pacific market for pharmaceutical companies.
